The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The study aims to explore the therapeutic value and mechanism of Interleukin-2 on children
with rheumatic diseases (Systemic Lupus Erythematosus, Primary Sjögren Syndrome, Juvenile
Idiopathic Arthritis).
Phase:
N/A
Details
Lead Sponsor:
First Hospital of Jilin University The First Hospital of Jilin University